Identifying druggable targets from active constituents of Azadirachta indica A. Juss. for non‐small cell lung cancer using network pharmacology and validation through molecular docking
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Identifying druggable targets from active constituents of Azadirachta indica A. Juss. for non‐small cell lung cancer using network pharmacology and validation through molecular docking
Authors
Keywords
-
Journal
PHYTOCHEMICAL ANALYSIS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-06-20
DOI
10.1002/pca.3254
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Natural alkaloids targeting EGFR in non-small cell lung cancer: Molecular docking and ADMET predictions
- (2022) Nidhi Saini et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Phytochemicals from Allium tuberosum Rottler ex Spreng Show Potent Inhibitory Activity against B-Raf, EGFR, K-Ras, and PI3K of Non-Small Cell Lung Cancer Targets
- (2022) Rajat Nath et al. Applied Sciences-Basel
- Chronicles of EGFR Tyrosine Kinase Inhibitors: Targeting EGFR C797S Containing Triple Mutations
- (2021) Krishna Babu Duggirala et al. Biomolecules & Therapeutics
- Corrigendum: Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway
- (2021) Anisha S. Jain et al. Frontiers in Oncology
- In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach
- (2021) Muthu Kumar Thirunavukkarasu et al. Pharmaceutics
- Network Pharmacology-Based Prediction and Verification of the Active Ingredients and Potential Targets of Zuojinwan for Treating Colorectal Cancer
- (2020) Siqi Huang et al. Drug Design Development and Therapy
- Clinical Significance of PIK3CA Gene in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis
- (2020) Yi Wang et al. Biomed Research International
- Phage lysin that specifically eliminates Clostridium botulinum Group I cells
- (2020) Zhen Zhang et al. Scientific Reports
- Associations between primary tumor RAS, BRAF and PIK3CA mutation status and metastatic site in patients with chemo-resistant metastatic colorectal cancer
- (2018) Troels Dreier Christensen et al. ACTA ONCOLOGICA
- EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients
- (2018) Hongyang Lu et al. OncoTargets and Therapy
- New Targets in Non–Small Cell Lung Cancer
- (2017) Soo J. Park et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort
- (2017) Kenji Sawa et al. LUNG CANCER
- PIK3CA mutations as prognostic factor in squamous cell lung carcinoma
- (2017) Marc McGowan et al. LUNG CANCER
- Effect of Size and Surface Charge of Gold Nanoparticles on their Skin Permeability: A Molecular Dynamics Study
- (2017) Rakesh Gupta et al. Scientific Reports
- SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
- (2017) Antoine Daina et al. Scientific Reports
- Therapeutics Role ofAzadirachta indica(Neem) and Their Active Constituents in Diseases Prevention and Treatment
- (2016) Mohammad A. Alzohairy Evidence-based Complementary and Alternative Medicine
- Scientific Advances in Lung Cancer 2015
- (2016) Anne S. Tsao et al. Journal of Thoracic Oncology
- Potential of neem ( Azadirachta indica L.) for prevention and treatment of oncologic diseases
- (2016) Shradha M. Patel et al. SEMINARS IN CANCER BIOLOGY
- Current Drugs and Drug Targets in Non-Small Cell Lung Cancer: Limitations and Opportunities
- (2015) Aditi Daga et al. Asian Pacific Journal of Cancer Prevention
- EGFR-L858R mutant enhances lung adenocarcinoma cell invasive ability and promotes malignant pleural effusion formation through activation of the CXCL12-CXCR4 pathway
- (2015) Meng-Feng Tsai et al. Scientific Reports
- Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
- (2014) S Li et al. BRITISH JOURNAL OF CANCER
- Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma
- (2014) Joseph Thaddeus Beck et al. CANCER TREATMENT REVIEWS
- STRING v10: protein–protein interaction networks, integrated over the tree of life
- (2014) Damian Szklarczyk et al. NUCLEIC ACIDS RESEARCH
- PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
- (2014) Lei Wang et al. PLoS One
- EGFR T790M Mutation: A Double Role in Lung Cancer Cell Survival?
- (2010) Kenichi Suda et al. Journal of Thoracic Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More